178 related articles for article (PubMed ID: 37315371)
1. Recent progress on tyrosine kinase 2 JH2 inhibitors.
Deng L; Wan L; Liao T; Wang L; Wang J; Wu X; Shi J
Int Immunopharmacol; 2023 Aug; 121():110434. PubMed ID: 37315371
[TBL] [Abstract][Full Text] [Related]
2. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
3. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
4. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
5. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Krueger JG; McInnes IB; Blauvelt A
J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
[TBL] [Abstract][Full Text] [Related]
7. Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors.
Zhang K; Ye K; Tang H; Qi Z; Wang T; Mao J; Zhang X; Jiang S
J Med Chem; 2023 Apr; 66(7):4378-4416. PubMed ID: 36951608
[TBL] [Abstract][Full Text] [Related]
8. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
Rusiñol L; Puig L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834806
[TBL] [Abstract][Full Text] [Related]
9. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of TYK2 pseudokinase domain stabilizers that allosterically inhibit TYK2 signaling.
Locke GA; Muckelbauer J; Tokarski JS; Barbieri CM; Belić S; Falk B; Tredup J; Wang YK
Methods Enzymol; 2022; 667():685-727. PubMed ID: 35525559
[TBL] [Abstract][Full Text] [Related]
11. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
12. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
13. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
He X; Chen X; Zhang H; Xie T; Ye XY
Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
[TBL] [Abstract][Full Text] [Related]
14. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.
Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2021 Nov; 27(12):2023-2030. PubMed ID: 34089259
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
Chang Y; Xu S; Ding K
J Med Chem; 2019 Oct; 62(20):8951-8952. PubMed ID: 31603320
[TBL] [Abstract][Full Text] [Related]
16. Progress on the Pharmacological Targeting of Janus Pseudokinases.
Henry SP; Jorgensen WL
J Med Chem; 2023 Aug; 66(16):10959-10990. PubMed ID: 37578217
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
18. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
Fang Z; Sun H; Wang Y; Sun Z; Yin M
Biomed Pharmacother; 2023 Nov; 167():115611. PubMed ID: 37778274
[TBL] [Abstract][Full Text] [Related]
19. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors.
Nogueira M; Puig L; Torres T
Drugs; 2020 Mar; 80(4):341-352. PubMed ID: 32020553
[TBL] [Abstract][Full Text] [Related]
20. Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides.
Tran NV; Nguyen LTA; Lim KW; Phan AT
Immunohorizons; 2021 Feb; 5(2):70-80. PubMed ID: 33542028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
